Supplementary Data for Apremilast versus betamethasone oral mini-pulse in the treatment of progressive non-segmental vitiligo: a non-inferiority randomized controlled trial

Mendeley Supplementary Figure 1. Proportion of patients achieving disease arrest in both treatment arms at each visit (per-protocol analysis)
Mendeley Supplementary Figure 2. Change in proportion of patients with different Vitiligo Disease Area (VIDA) Score in each treatment arm over study duration, A. Apremilast, B. Betamethasone oral mini-pulse (no intergroup difference, p=0.337)